|
| PROGRAMS AS OF JULY 21st |
 |
SESSION II
CONVENTIONAL DIABETES THERAPIES: OUTCOMES AND LIMITATIONS
(10:20 am–12:00 pm)
Session Chair
Harold Lebovitz (USA)
Program Committee
Stephanie Amiel (UK)
John Buse (USA)
David Simmons (UK)
Objectives
• To discuss the benefits and deficiencies of current diabetes therapies
• To highlight the metabolic advantages and disadvantages of current therapies as contrasted to interventional therapies
Keynote Lectures
Outcomes of Current and Soon-to-be-Available Pharmacologic Therapies:
• Benefits and Positive Aspects- John Buse (USA)
• Down Sides- Stephanie Amiel (UK))
Panel Discussion
Metabolic Advantages and Disadvantages of Current Therapies as Contrasted to Interventional Therapies
Moderators
Harold Lebovitz (USA)
David Simmons (UK)
Panelists
Stefano Del Prato (Italy)
Nick Finer (UK)
Allison Goldfine (USA)
Jeffrey Mechanick (USA)
Philip Schauer (USA))
|